AP3346A - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same - Google Patents
Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the sameInfo
- Publication number
- AP3346A AP3346A AP2012006191A AP2012006191A AP3346A AP 3346 A AP3346 A AP 3346A AP 2012006191 A AP2012006191 A AP 2012006191A AP 2012006191 A AP2012006191 A AP 2012006191A AP 3346 A AP3346 A AP 3346A
- Authority
- AP
- ARIPO
- Prior art keywords
- same
- preparing
- pharmaceutical composition
- composition containing
- novel compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090095363 | 2009-10-07 | ||
| PCT/KR2010/006760 WO2011043568A2 (fr) | 2009-10-07 | 2010-10-04 | Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2012006191A0 AP2012006191A0 (en) | 2012-04-30 |
| AP3346A true AP3346A (en) | 2015-07-31 |
Family
ID=43857261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006191A AP3346A (en) | 2009-10-07 | 2010-10-04 | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8729273B2 (fr) |
| EP (1) | EP2467378B1 (fr) |
| JP (1) | JP5702392B2 (fr) |
| KR (1) | KR101751325B1 (fr) |
| CN (1) | CN102574839B (fr) |
| AP (1) | AP3346A (fr) |
| AR (1) | AR078504A1 (fr) |
| AU (1) | AU2010304091B2 (fr) |
| BR (1) | BR112012007828B8 (fr) |
| CA (1) | CA2774133C (fr) |
| CL (1) | CL2012000738A1 (fr) |
| CO (1) | CO6430501A2 (fr) |
| EA (1) | EA021025B1 (fr) |
| EC (1) | ECSP12011793A (fr) |
| ES (1) | ES2599829T3 (fr) |
| IL (1) | IL218669A (fr) |
| MA (1) | MA33880B1 (fr) |
| MX (1) | MX2012003782A (fr) |
| MY (1) | MY162813A (fr) |
| PE (1) | PE20121088A1 (fr) |
| SG (1) | SG179186A1 (fr) |
| TR (1) | TR201203989T1 (fr) |
| TW (1) | TWI423962B (fr) |
| UA (1) | UA110197C2 (fr) |
| WO (1) | WO2011043568A2 (fr) |
| ZA (1) | ZA201202544B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| EP3243515B1 (fr) * | 2011-08-30 | 2019-10-16 | CHDI Foundation, Inc. | Inhibiteurs de kynurenine-3-monooxygenase, compositions pharmaceutiques et leurs procédés d'utilisation |
| LT2980085T (lt) | 2013-03-29 | 2018-05-10 | Teijin Pharma Limited | Pirazolo darinys |
| AP2017009724A0 (en) | 2014-07-17 | 2017-01-31 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
| CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
| US10266496B2 (en) * | 2015-09-02 | 2019-04-23 | Sunshine Lake Pharma Co., Ltd. | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| US12161696B2 (en) | 2016-12-02 | 2024-12-10 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CN110612286A (zh) * | 2017-02-28 | 2019-12-24 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
| TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療ａ型血友病的方法 |
| IL276783B2 (en) * | 2018-06-01 | 2023-12-01 | Autophagysciences Inc | The composition and pharmaceutical compound containing it |
| CN111072647B (zh) * | 2019-12-11 | 2021-02-26 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
| CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
| MY208699A (en) * | 2020-11-04 | 2025-05-25 | Lg Chemical Ltd | Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same |
| MX2023005461A (es) * | 2020-12-01 | 2023-05-22 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion. |
| EP4257123A4 (fr) * | 2020-12-01 | 2024-05-08 | Lg Chem, Ltd. | Formulation orale stable contenant de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique |
| CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途 |
| PE20240764A1 (es) * | 2021-04-16 | 2024-04-17 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico |
| WO2022231261A1 (fr) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | Procédé de préparation d'un intermédiaire pour la synthèse d'un inhibiteur de la xanthine oxydase |
| KR102708081B1 (ko) * | 2021-04-27 | 2024-09-20 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
| KR20220147531A (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제의 제조 방법 |
| CA3218011A1 (fr) * | 2021-05-07 | 2022-11-10 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | Un inhibiteur de xanthine oxydase |
| CN117412746A (zh) | 2021-06-15 | 2024-01-16 | 株式会社Lg化学 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Ｌｇ化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
| WO2023277658A1 (fr) * | 2021-07-02 | 2023-01-05 | 주식회사 엘지화학 | Procédé de préparation d'un intermédiaire pour la synthèse d'un inhibiteur de la xanthine oxydase |
| US20250289809A1 (en) * | 2022-04-27 | 2025-09-18 | Atom Bioscience America Corporation | Compounds useful for gout |
| CN116715633B (zh) * | 2022-04-27 | 2025-08-12 | 杭州新元素药业股份有限公司 | 可用于降尿酸的化合物 |
| CN116283946B (zh) * | 2023-03-27 | 2024-05-07 | 武汉工程大学 | 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用 |
| WO2025014292A1 (fr) * | 2023-07-10 | 2025-01-16 | 주식회사 엘지화학 | Procédé de préparation d'intermédiaires pour synthétiser un inhibiteur de la xanthine oxydase |
| CN118598859B (zh) * | 2024-05-21 | 2025-08-19 | 武汉工程大学 | 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011131A2 (fr) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Composés amidés |
| WO2008126898A1 (fr) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | Dérivé d'(aza)indole et ses usages médicaux |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073981C (fr) | 1990-11-30 | 2002-01-08 | Shiro Kondo | Derives de 2-arylthiazole et composition pharmaceutique a base de ces derives |
| ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| JP2004502686A (ja) * | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| ES2250422T3 (es) * | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| KR20080035594A (ko) | 2005-07-01 | 2008-04-23 | 닛뽕 케미파 가부시키가이샤 | 크산틴옥시다아제 저해제 |
| DE602006018635D1 (de) | 2005-10-07 | 2011-01-13 | Astellas Pharma Inc | Triarylcarbonsäurederivat |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
| WO2008126770A1 (fr) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | Procédé de production d'un dérivé d'acide triarylcarboxylique |
| EP2133331A4 (fr) | 2007-04-11 | 2011-06-22 | Kissei Pharmaceutical | Dérivé hétérocyclique à 5 éléments et ses usages médicaux |
| WO2010044404A1 (fr) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | Derive heterocyclique fusionne et son utilisation a des fins medicales |
| CA2912970C (fr) | 2008-10-16 | 2017-04-18 | James M. Tuyls | Dispositif et procede et plateau tournant pour distribuer un produit alimentaire sur demande |
| US8785489B2 (en) * | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| CA2771026A1 (fr) * | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Derives d'indole utilises comme modulateurs de crac |
-
2010
- 2010-10-01 TW TW099133473A patent/TWI423962B/zh active
- 2010-10-04 AP AP2012006191A patent/AP3346A/xx active
- 2010-10-04 BR BR112012007828A patent/BR112012007828B8/pt active IP Right Grant
- 2010-10-04 AU AU2010304091A patent/AU2010304091B2/en active Active
- 2010-10-04 CN CN201080044868.1A patent/CN102574839B/zh active Active
- 2010-10-04 MA MA34731A patent/MA33880B1/fr unknown
- 2010-10-04 UA UAA201204342A patent/UA110197C2/ru unknown
- 2010-10-04 EP EP10822213.4A patent/EP2467378B1/fr active Active
- 2010-10-04 WO PCT/KR2010/006760 patent/WO2011043568A2/fr not_active Ceased
- 2010-10-04 ES ES10822213.4T patent/ES2599829T3/es active Active
- 2010-10-04 MX MX2012003782A patent/MX2012003782A/es active IP Right Grant
- 2010-10-04 EA EA201270520A patent/EA021025B1/ru unknown
- 2010-10-04 SG SG2012018768A patent/SG179186A1/en unknown
- 2010-10-04 TR TR2012/03989T patent/TR201203989T1/xx unknown
- 2010-10-04 US US13/498,253 patent/US8729273B2/en active Active
- 2010-10-04 CA CA2774133A patent/CA2774133C/fr active Active
- 2010-10-04 JP JP2012533074A patent/JP5702392B2/ja active Active
- 2010-10-04 KR KR1020100096578A patent/KR101751325B1/ko active Active
- 2010-10-04 PE PE2012000438A patent/PE20121088A1/es active IP Right Grant
- 2010-10-04 MY MYPI2012700104A patent/MY162813A/en unknown
- 2010-10-05 AR ARP100103609A patent/AR078504A1/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218669A patent/IL218669A/en active IP Right Grant
- 2012-03-23 CL CL2012000738A patent/CL2012000738A1/es unknown
- 2012-03-23 EC ECSP12011793 patent/ECSP12011793A/es unknown
- 2012-03-23 CO CO12049241A patent/CO6430501A2/es active IP Right Grant
- 2012-04-10 ZA ZA2012/02544A patent/ZA201202544B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011131A2 (fr) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Composés amidés |
| WO2008126898A1 (fr) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | Dérivé d'(aza)indole et ses usages médicaux |
Non-Patent Citations (1)
| Title |
|---|
| KELVIN BILLINGSLEY ET AL: "Highly Efficient Monophosphine-Based Catalyst for the Palladium-Catalyzed Suzuki-Miyaura Reaction of Heteroaryl Halides and Heteroaryl Boronic Acids and Esters", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 11, 1 March 2007 (2007-03-01), pages 3358 - 3366, XP055056735 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3346A (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
| HUS1700051I1 (hu) | Pirrolopiridin vegyületek, mint CDK inhibitorok | |
| ZA201608799B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| ZA201208198B (en) | Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same | |
| EP2464626A4 (fr) | Procedes, composes, et compositions pour administrer de l'acide 1,3-propane disulfonique | |
| WO2010093191A3 (fr) | Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant | |
| ZA201209297B (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| IL207099A0 (en) | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace) | |
| ZA201203183B (en) | Sulfomethylsuccinates, process for making same and compositions containing same | |
| IL211018A (en) | Inhibitors, processes for making them, medicinal preparations containing them and their use | |
| MY144726A (en) | Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them | |
| IL216388A0 (en) | New compounds, pharmaceutical composition and methods relating thereto | |
| EP2439198A4 (fr) | Nouveau procédé de préparation de rosuvastatine, composés intermédiaires utiles pour préparer de la rosuvastatine, et procédé de préparation correspondant | |
| ZA201103444B (en) | Heteroaromatic compounds for use as hif inhibitors | |
| IL207183A (en) | Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions | |
| GB0800570D0 (en) | Composition, process for preparation and method of use | |
| IL203064B (en) | A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound | |
| AP2011005885A0 (en) | Flavanoid compounds and process for preparation thereof. | |
| IL212850A0 (en) | Novel method for the preparation of granulates of active constituents, and granulates as obtained | |
| AP2012006352A0 (en) | AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same. | |
| IL210049A0 (en) | Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it | |
| SI2332910T1 (sl) | Novi derivati azabiciklo(3.2.0)hept-3-ila, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| HK1171733A (en) | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid | |
| EP2289989A4 (fr) | Additif, son procédé de fabrication et composition le contenant | |
| HK1162499A (en) | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 |